Newsflash: BYDUREON Pen to Be Discontinued
Effective March 2021, AstraZeneca will discontinue distribution of BYDUREON Pen. Patients should be switched to Bydureon BCise.
Coming Oct 6th! Special Report:
The first installment of "The Future of Type 2 Diabetes Management and The Changing Roles of Healthcare Professionals."
Adherence-related issues are hemorrhaging the costs of diabetes-related treatment in America. To offset this tragedy, GlucosePATH is utilized by a team of healthcare professionals dedicated to improving the quality of life while decreasing avoidable costs. Don't miss this special feature, exclusively in Diabetes in Control. | 
When we add medications for our patients, our focus is usually directed by such things as A1C, Time in Range, maximum highs and the like. However, when we add these medications we often don’t see a noticeable difference in the aforementioned parameters.